Shares of Sun Pharmaceutical Industries rose around 2 percent and hit a 52-week high of Rs 1,606.75 on March 6 afternoon after the US Food and Drugs Administration reportedly gave the company's Ankleshwar API (Active Pharmaceutical Ingredients) unit the all-clear to manufacture and export.
A CNBC Awaaz report said the USFDA classified the unit as No Action Indicated (NAI), paving the way for manufacturing and export from the plant.
The NAI classification issued by the US FDA is the most sought after and corresponds to the highest level of compliance.
At 2.57 pm, Sun Pharma was trading at Rs 1,605.30 on the NSE.
Follow our market blog to catch all the live updates
Investors cheered the development, more so since the company has struggled with the adverse impacts of an import alert for its Halol unit and another compliance snag at its Mohali facility in recent times. These regulatory troubles have put pressure on the drugmaker's US market revenue.
Shares of Sun Pharma have gained 29 percent in the past three months.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
